Core Insights - IMAC Holdings, Inc. has appointed Dr. Peter Beitsch and Dr. Matthew Schwartz to its Board of Directors, effective June 26, 2024, to enhance its position in proteomics and precision medicine [1][4] Group 1: Board Appointments - Dr. Matthew Schwartz has over 18 years of experience in cancer care using radiotherapy and precision oncology, currently serving as a Radiation Oncologist [2] - Dr. Peter Beitsch has a strong background in surgical oncology and genomics, actively involved in breast cancer research [3] - The expertise of both doctors is expected to guide the company's strategic initiatives and enhance research capabilities [3] Group 2: Company Vision and Strategy - The appointments are part of IMAC's strategy to advance innovation in proteomics and empower researchers and oncologists with cutting-edge solutions [4] - IMAC, through its subsidiary Ignite Proteomics, aims to revolutionize proteomics research using innovative technologies like Reverse Phase Protein Arrays (RPPA) [4]
IMAC Holdings, Inc. Appoints Dr. Matthew Schwartz and Dr. Peter Beitsch to Board of Directors